- Indonesia detains 18 in pre-emptive bid to boost Christmas security
- Saudi Arabia says cinemas will be allowed from early 2018
- U.S. citizen on the run after busting out of Bali prison
- Indian police arrests French journalist after filming in Kashmir
- Indian police file sexual assault case against airline passenger for a
- Roche: Tecentriq cocktail slows kidney cancer progression
- Merck raises stakes in lung cancer as rivals close in
- Venezuela's Maduro: Some opposition parties to be barred from presidential vote
- Alabama race epitomizes the turbulence of the Trump era
- Bahraini civil society group under pressure after Israel visit
- Buoyed by mayoral votes, Venezuela's socialists eye 2018 presidency ra
- 'Walking Dead' sets stage for key death
- China starts formal legal proceedings against disgraced senior politic
- Venezuela socialists winning local vote, Maduro joyous
- Bitcoin jumps after futures trading begins
- Six New Street Fighter 5 Characters Revealed For Season 3 Of Content
- China, Taiwan spar over Chinese diplomat's invasion threat
- Israeli army destroys tunnel from Gaza
- With foes abstaining, Venezuela mayoral contests to boost socialists
- Futures trading arrives for bitcoin
FDA approves heart protection claims for Amgen cholesterol drug
(Reuters) - Amgen Inc can now promote the ability of its potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes, after U.S. health regulators approved adding those benefits to the medicine’s prescribing label, the company said on Friday.
Amgen has long seen this development as critical to clearing onerous hurdles to patient access and unlocking the value of the drug, Repatha, which has had anemic sales since its August 2015 approval despite its billion-dollar potential.
The injected biotech drug was approved on the basis of its ability to dramatically lower bad LDL cholesterol.
But health insurers and pharmacy benefit managers have made it extremely difficult for patients to get the medicine, even those whose dangerously high cholesterol met criteria for use in the original label approved by the Food and Drug Administration.
As many as 75 percent of patients prescribed the medicine have been denied coverage despite numerous appeals, severely holding back sales. Repatha sales, while gradually improving, were just $89 million in the third quarter.
A study released in March of more than 27,500 patients showed that Repatha cut the risk of heart attacks by 27 percent and stroke by 21 percent compared with a placebo in high-risk patients already on high doses of cholesterol-lowering statins such as Pfizer Inc’s Lipitor. In the second year of the study, the benefits were more pronounced, with a combined heart attack and stroke risk reduction of 33 percent.
But Amgen by law was unable to promote those benefits until the FDA approved adding those claims. The company has repeatedly said having the heart benefits added to the official label was necessary to get insurers to loosen their purse strings.
“With this approval, it’s now more important than ever that appropriate patients obtain access to Repatha in order to avoid preventable heart attacks and strokes,” Tony Hooper, Amgen’s head of global commercial operations, said in a statement.
“We will continue to work with payers to help ensure the patients who need Repatha the most are able to get this innovative medicine,” Hooper said.
Reporting by Bill Berkrot; Editing by David Gregorio
Our Standards:The Thomson Reuters Trust Principles.